- 同
- hepatitis B core antigen
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial-ANRS HB02 VAC-ADN.
- Fontaine H1, Kahi S2, Chazallon C2, Bourgine M3, Varaut A4, Buffet C5, Godon O3, Meritet JF6, Saïdi Y2, Michel ML3, Scott-Algara D7, Aboulker JP2, Pol S1; ANRS HB02 study group.
- Gut.Gut.2015 Jan;64(1):139-47. doi: 10.1136/gutjnl-2013-305707. Epub 2014 Feb 20.
- OBJECTIVE: The antiviral efficacy of nucleos(t)ide analogues whose main limitation is relapse after discontinuation requires long-term therapy. To overcome the risk of relapse and virological breakthrough during long-term therapy, we performed a phase I/II, open, prospective, multicentre trial using
- PMID 24555998
- An N-terminal extension to the hepatitis B virus core protein forms a poorly ordered trimeric spike in assembled virus-like particles.
- McGonigle R1, Yap WB2, Ong ST2, Gatherer D1, Bakker SE1, Tan WS3, Bhella D4.
- Journal of structural biology.J Struct Biol.2014 Dec 31. pii: S1047-8477(14)00280-9. doi: 10.1016/j.jsb.2014.12.006. [Epub ahead of print]
- Virus-like particles composed of the core antigen of hepatitis B virus (HBcAg) have been shown to be an effective platform for the display of foreign epitopes in vaccine development. Heterologous sequences have been successfully inserted at both amino and carboxy termini as well as internally at the
- PMID 25557498
- An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation.
- Xue M, Fan F, Ding L, Liu J, Su S, Yin P, Cao M, Hu H, Wang L.
- Journal of translational medicine.J Transl Med.2014 Dec 20;12(1):361. [Epub ahead of print]
- BackgroundFor more than 240 million chronic HBV carriers worldwide, effective therapeutic HBV vaccines are urgently needed. Recently, we demonstrated that autophagosomes were efficient antigens carriers and capable to cross-prime robust T-cell responses and mediate regression of multiple established
- PMID 25526800
Japanese Journal
- エンテカビル・ペグインターフェロンα-2b併用48週治療にてHBs抗原が消失したB型慢性肝炎の1例
- 犬塚 義,大崎 往夫,松田 史博 [他],坂本 梓,幡丸 景一,邉見 慎一郎,石川 哲朗,齋藤 澄夫,西川 浩樹,喜多 竜一,岡部 純弘,木村 達,若狭 朋子,萩原 智,工藤 正俊
- 肝臓 53(1), 42-47, 2012-01-25
- 症例は65歳の日本人男性.2008年12月にB型慢性肝炎(Genotype C)指摘され,2009年12月よりエンテカビル(0.5 mg/日)とペグインターフェロンα-2b(80 μg/週)の48週間併用治療を開始.その後ウイルス量・HBe抗原価・HBs抗原価の減少を認めた.開始後44週時点でウイルス量は検出感度以下になるとともに,HBeセロコンバージョン・HBs抗原の消失,48週治療後半年以上経 …
- NAID 10030240845
- C型慢性肝炎に対するインターフェロン著効13年後に肝組織中ウイルス陰性の状態から発症した肝細胞癌の1例
- 矢倉 道泰,田中 晃久,上司 裕史
- 肝臓 50(6), 238-243, 2009-05-25
- C型慢性肝炎に対するインターフェロン投与で著効になったにもかかわらず13年後に発癌し,しかもその肝組織中のHCV RNAプラス鎖,マイナス鎖を調べた結果,いずれも検出されなかった1例を経験したので報告する.症例は75歳の男性で1994年よりC型慢性肝炎で当院に通院していた.肝生検ではF1A1であった.HCVはgenotypeIIa.IFNα2aを24週間投与し著効になった. 以後半年に一回,採血と …
- NAID 10024805160
- HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes
- CHEN Weiwei,SHI Ming,SHI Feng,MAO Yuanli,TANG Zirong,ZHANG Bin,ZHANG Hui,CHEN Liangen,CHEN Liming,XIN Shaojie,WANG Fu-sheng
- Hepatology research : the official journal of the Japan Society of Hepatology 39(4), 355-365, 2009-04-01
- NAID 10025325364
Related Links
- HBcAg hepatitis B core antigen. HB c Ag abbr. hepatitis B core antigen antigen [an´tĭ-jen] any substance capable, under appropriate conditions, of inducing a specific immune response and reacting with the products of that response ...
- Hbcag definition at Dictionary.com, a free online dictionary with pronunciation, synonyms and translation. Look it up now! Thesaurus Translate Puzzles & Games Reference Word of the Day Blog Slideshows Apps by Dictionary ...
Related Pictures
★リンクテーブル★
[★]
- 同
- HBcAg
- 同
- HBcAG